Skip to main content
Top

Clinical & Experimental Metastasis

Issue 7/1999

Content (11 Articles)

bcl-2 and c-erbB-2 proteins are involved in the regulation of VEGF and of thymidine phosphorylase angiogenic activity in non-small-cell lung cancer

Michael I. Koukourakis, Alexandra Giatromanolaki, Keneth J. O'Byrne, Jiles Cox, Barbara Krammer, Kevin C. Gatter, Adrian L. Harris

Expression of matrix metalloproteinases and their inhibitors in human brain tumors

Zarin Kachra, Edith Beaulieu, Louis Delbecchi, Nathalie Mousseau, France Berthelet, Robert Moumdjian, Rolando Del Maestro, Richard Béliveau

Growth-associated changes in glutathione content correlate with liver metastatic activity of B16 melanoma cells

Julian Carretero, Elena Obrador, Miren J. Anasagasti, Javier J. Martin, Fernando Vidal-Vanaclocha, José M. Estrela

Antiangiogenic, antitumoural and antimetastatic effects of two distamycin A derivatives with anti-HIV-1 Tat activity in a Kaposi's sarcoma-like murine model

Laura Possati, Diana Campioni, Francesco Sola, Luciana Leone, Luigi Ferrante, Cecilia Trabanelli, Marina Ciomei, Marco Montesi, Romina Rocchetti, Simona Talevi, Stefano Bompadre, Antonella Caputo, Giuseppe Barbanti-Brodano, Alfredo Corallini

Genetic diagnosis of micrometastasis based on SCC antigen mRNA in cervical lymph nodes of head and neck cancer

Hiroyuki Hamakawa, Masakuni Fukizumi, Yang Bao, Tomoki Sumida, Akiko Onishi, Hiroaki Tanioka, Hidemitsu Sato, Eiji Yumoto

Metastasis-suppressed C8161 melanoma cells arrest in lung but fail to proliferate

Steven F. Goldberg, John F. Harms, Kim Quon, Danny R. Welch

Downregulation of the urokinase-type plasminogen activator receptor through inhibition of translation by antisense oligonucleotide suppresses invasion of human glioblastoma cells

Pamarthi M. Mohan, Sajani S. Lakka, Sanjeeva Mohanam, Yoshiaki Kin, Raymond Sawaya, Anthanassios P. Kyritsis, Garth L. Nicolson, Jasti S. Rao

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine